Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exogenous surfactant therapy for ARDS.

Adam Maruscak1, Jim F Lewis

  • 1St. Joseph's Health Centre, London, ON, N6A 4V2, Canada.

Expert Opinion on Investigational Drugs
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins.

Scientific reports·2018
Same author

Apolipoprotein E-deficient mice are susceptible to the development of acute lung injury.

Respiration; international review of thoracic diseases·2014
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Acute respiratory distress syndrome (ARDS) involves surfactant system dysfunction. While exogenous surfactant is effective for neonates, its use in ARDS patients is still under investigation due to complex lung injury, with future research showing potential feasibility.

Area of Science:

  • Pulmonary Medicine
  • Critical Care Medicine
  • Biomedical Research

Background:

  • Acute respiratory distress syndrome (ARDS) is characterized by surfactant system dysfunction, irrespective of the underlying cause.
  • Exogenous surfactant therapy is a proven treatment for neonatal respiratory distress syndrome.
  • Current therapeutic options for ARDS do not effectively address the complex lung injury involved.

Purpose of the Study:

  • To evaluate the efficacy of exogenous surfactant therapy in patients with acute respiratory distress syndrome.
  • To explore the challenges and potential future applications of surfactant replacement therapy in ARDS.

Main Methods:

  • Review of clinical trial data regarding exogenous surfactant administration in ARDS patients.
  • Analysis of the pathophysiological mechanisms underlying surfactant dysfunction in ARDS.

Related Experiment Videos

  • Examination of ongoing and future research directions for surfactant therapy in ARDS.

    • Main Results:

    • Clinical trials to date have not demonstrated improved survival rates in ARDS patients treated with exogenous surfactant.
    • The complexity of lung injury in ARDS presents a significant barrier to effective surfactant therapy.
    • Despite current limitations, research suggests potential feasibility for future surfactant-based treatments.

    Conclusions:

    • Surfactant system dysfunction is a key feature of ARDS, but exogenous surfactant therapy has not yet proven effective for improving survival.
    • Further research is necessary to overcome the complexities of ARDS lung injury and establish the feasibility of surfactant therapy.